Name: DGN549-C
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

IUPAC Name

N'-[(2S)-1-[[(2S)-1-[3-[[(12aS)-8-methoxy-6-oxo-12a,13-dihydroindolo[2,1-c][1,4]benzodiazepin-9-yl]oxymethyl]-5-[[(12aS)-8-methoxy-6-oxo-11,12,12a,13-tetrahydroindolo[2,1-c][1,4]benzodiazepin-9-yl]oxymethyl]anilino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-N-[2-(2,5-dioxopyrrol-1-yl)ethyl]hexanediamide

Canonical SMILES

CC(C(=O)NC(C)C(=O)NC1=CC(=CC(=C1)COC2=C(C=C3C(=C2)N=CC4CC5=CC=CC=C5N4C3=O)OC)COC6=C(C=C7C(=C6)NCC8CC9=CC=CC=C9N8C7=O)OC)NC(=O)CCCCC(=O)NCCN1C(=O)C=CC1=O

InChI

InChI=1S/C60H61N9O12/c1-34(64-54(71)16-10-9-15-53(70)61-19-20-67-55(72)17-18-56(67)73)57(74)65-35(2)58(75)66-40-22-36(32-80-51-28-45-43(26-49(51)78-3)59(76)68-41(30-62-45)24-38-11-5-7-13-47(38)68)21-37(23-40)33-81-52-29-46-44(27-50(52)79-4)60(77)69-42(31-63-46)25-39-12-6-8-14-48(39)69/h5-8,11-14,17-18,21-23,26-30,34-35,41-42,63H,9-10,15-16,19-20,24-25,31-33H2,1-4H3,(H,61,70)(H,64,71)(H,65,74)(H,66,75)/t34-,35-,41-,42-/m0/s1

Solubility

10 mm in DMSO

Shelf Life

-20°C 3 years powder; -80°C 2 years in solvent

Shipping

Room temperature, or blue ice upon request.

Storage

-20°C

DGN549-C is a versatile compound with multiple applications in the bioscience sector. Here are some key applications of DGN549-C:

Cancer Research: DGN549-C is used in cancer research for its potential to inhibit tumor growth and induce apoptosis in cancerous cells. Researchers utilize DGN549-C to study its mechanism of action and its effects on various cancer cell lines. This aids in discovering new therapeutic strategies and developing anti-cancer drugs.

Drug Discovery: DGN549-C serves as a lead compound in drug discovery programs aimed at developing treatments for various diseases. By assessing the bioactivity and safety profile of DGN549-C, researchers can identify promising drug candidates. This facilitates the development of new medications with enhanced efficacy and reduced side effects.

Pharmacokinetics Studies: DGN549-C is employed in pharmacokinetic studies to evaluate its absorption, distribution, metabolism, and excretion (ADME) properties. Understanding the pharmacokinetics of DGN549-C helps in optimizing its formulation and dosing regimens for therapeutic use. This information is essential for ensuring the safety and effectiveness of the compound in clinical settings.

Biological Pathways Research: DGN549-C is used to probe and manipulate biological pathways related to disease mechanisms and cellular functions. By treating cells or model organisms with DGN549-C, researchers can investigate its impact on specific signaling pathways and gene expression profiles. This contributes to a deeper understanding of disease biology and identification of novel therapeutic targets.

Catalog	Product Name	CAS	Inquiry
BADC-00747	DGN549

What is DGN549-C?

DGN549-C is a small-molecule cytotoxin conjugate designed for ADC applications. It incorporates a potent cytotoxic payload with a cleavable linker system, facilitating selective intracellular release after antibody-mediated endocytosis and supporting targeted therapeutic research.

18/12/2018

Dear team, how does DGN549-C release its payload?

DGN549-C releases its cytotoxic payload via a linker cleaved by intracellular proteases. This controlled release ensures selective activity in target cells, enhancing therapeutic index and minimizing systemic toxicity during ADC research.

17/2/2020

Dear team, what are the research applications of DGN549-C?

DGN549-C is used in oncology ADC research for preclinical and early clinical evaluation. It allows assessment of intracellular payload release, cytotoxicity, and pharmacokinetics, supporting optimization of ADC design and efficacy studies.

9/2/2019

Dear BOC Sciences, may I ask what stability features DGN549-C provides?

The cleavable linker in DGN549-C maintains ADC stability in plasma, preventing premature payload release. This ensures consistent delivery of the cytotoxin to target cells and improves reproducibility in experimental ADC studies.

17/4/2020

Good afternoon! Could you confirm if DGN549-C can be conjugated to various antibodies?

Yes, DGN549-C is compatible with multiple monoclonal antibodies through standard conjugation chemistries. This flexibility allows researchers to customize ADCs for specific targets and optimize therapeutic outcomes.

27/8/2018

— Dr. Laura Bennett, Senior Scientist (USA)

DGN549-C enabled highly reproducible cytotoxicity assays with minimal variability.

9/2/2019

— Dr. Michael Carter, ADC Chemist (UK)

Batch uniformity and solubility made DGN549-C easy to handle for multiple conjugation steps.

27/8/2018

— Mr. Peter Novak, Medicinal Chemist (Czech Republic)

The DGN549-C compound from BOC Sciences has been critical in advancing our ADC platform. Its superior chemical profile ensured consistent results, making it one of the most reliable reagents we have used.

17/4/2020

— Mr. Ryan Miller, Associate Scientist (Canada)

Our initial studies with DGN549-C from a different vendor were inconsistent. We switched to BOC Sciences and immediately saw a dramatic improvement. The batch purity was exceptional, and it significantly enhanced our in vitro assay results. This product is now our go-to for this specific application.

18/12/2018

— Mr. Ben Schmidt, Scientist (Canada)

We were impressed by the purity and performance of DGN549-C. It significantly improved our in vitro results compared to previous batches from other vendors.

— Dr. Isabel Laurent, Biomedical Researcher (France)

We used DGN549-C from BOC Sciences for ADC mechanism studies. The compound was highly reliable and well-characterized, allowing us to achieve consistent data across multiple experimental setups.

17/2/2020